Literature DB >> 12532083

Inflammatory cells in asthma: mechanisms and implications for therapy.

Qutayba Hamid1, Meri K Tulic', Mark C Liu, Redwan Moqbel.   

Abstract

Recent clinical studies have brought asthma's complex inflammatory processes into clearer focus, and understanding them can help to delineate therapeutic implications. Asthma is a chronic airway inflammatory disease characterized by the infiltration of airway T cells, CD(+) (T helper) cells, mast cells, basophils, macrophages, and eosinophils. The cysteinyl leukotrienes also are important mediators in asthma and modulators of cytokine function, and they have been implicated in the pathophysiology of asthma through multiple mechanisms. Although the role of eosinophils in asthma and their contribution to bronchial hyperresponsiveness are still debated, it is widely accepted that their numbers and activation status are increased. Eosinophils may be targets for various pharmacologic activities of leukotriene receptor antagonists through their ability to downregulate a number of events that may be key to the effector function of these cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532083     DOI: 10.1067/mai.2003.22

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  30 in total

1.  Effects of Angelicin on Ovalbumin (OVA)-Induced Airway Inflammation in a Mouse Model of Asthma.

Authors:  Da-Zhen Wei; Xian-Yang Guo; Li-Na Lin; Meng-Xiang Lin; Yu-Qiang Gong; Bin-Yu Ying; Ming-Yuan Huang
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

2.  Semaphorin3E/plexinD1 Axis in Asthma: What We Know So Far!

Authors:  Latifa Koussih; Abdelilah S Gounni
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma.

Authors:  Shutang Zhou; Erin N Potts; Frank Cuttitta; W Michael Foster; Mary E Sunday
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-20       Impact factor: 11.205

4.  Montelukast in asthma: a review of its efficacy and place in therapy.

Authors:  Pierluigi Paggiaro; Elena Bacci
Journal:  Ther Adv Chronic Dis       Date:  2011-01       Impact factor: 5.091

Review 5.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

6.  Characterization of leukotrienes in a pilot study of older asthma subjects.

Authors:  Sharmilee M Nyenhuis; Elizabeth A Schwantes; Sameer K Mathur
Journal:  Immun Ageing       Date:  2010-07-05       Impact factor: 6.400

7.  Primary murine airway smooth muscle cells exposed to poly(I,C) or tunicamycin synthesize a leukocyte-adhesive hyaluronan matrix.

Authors:  Mark E Lauer; Durba Mukhopadhyay; Csaba Fulop; Carol A de la Motte; Alana K Majors; Vincent C Hascall
Journal:  J Biol Chem       Date:  2008-12-16       Impact factor: 5.157

8.  Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype.

Authors:  Selina Hom; Michele Pisano
Journal:  P T       Date:  2017-09

Review 9.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

10.  Proinflammatory and Th2 cytokines regulate the high affinity IgE receptor (FcepsilonRI) and IgE-dependant activation of human airway smooth muscle cells.

Authors:  Naresh Singh Redhu; Ali Saleh; Lianyu Shan; William T Gerthoffer; Sam K Kung; Andrew J Halayko; Bouchaib Lamkhioued; Abdelilah S Gounni
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.